natgillin/translations-raw huggingface dataset:
The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea. 
Simptomi lahko vključujejo hladno znojenje, utrujenost, glavobol, hitro bitje srca, občutek lakote, razdražljivost, živčnost ali siljenje na bruhanje.
Allergic reactions have been reported with frequency not known (cannot be estimated from the available data) in patients taking Tandemact. 
Pri bolnikih, ki jemljejo zdravilo Tandemact, so poročali o alergijskih reakcijah z neznano pogostnostju (iz razpoložljivih podatkov je ni mogoče oceniti).
4.7 Effects on ability to drive and use machines Tandemact has minor influence on the ability to drive and use machines. 
Zdravilo Tandemact ima blag vpliv na sposobnost vožnje in upravljanja s stroji.
Each tablet contains approximately 177 mg lactose monohydrate (see section 4.4). 
Ena tableta vsebuje približno 177 mg laktoze monohidrata (glejte poglavje 4.4).
Some patients experienced the following side effects whilst taking pioglitazone and sulphonylureas, including glimepiride: 
Nekateri bolniki med jemanjem pioglitazona in sulfonilsečnin, vključno z glimepiridom, izkusijo naslednje neželene učinke:
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. 
Poročali so, da sočasno dajanje pioglitazona z rifampicinom (induktor citokroma P450 2C8) povzroči 54% zmanjšanje AUC pioglitazona.
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
V obdobju trženja zdravila so poročali o primerih srčnega popuščanja, ko so pioglitazon uporabljali v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja.
Each tablet contains approximately 214 mg lactose monohydrate (see section 4.4). 
Ena tableta vsebuje približno 214 mg laktoze monohidrata (glejte poglavje 4.4).
If you experience any of these, talk to your doctor as soon as possible. 
Če opazite kar koli od naštetega, se čim prej posvetujte s svojim zdravnikom.
Glimepiride inhibits the glucose production in the liver by increasing the intracellular concentration of fructose-2,6-bisphosphate, which in turn inhibits the gluconeogenesis. 
Glimepirid poveča znotrajcelično koncentracijo fruktoza-2,6-bisfosfata, kar zavira glukoneogenezo in zato s tem zavira glukoneogenezo.
Each tablet contains approximately 125 mg lactose monohydrate (see section 4.4). 
Ena tableta vsebuje približno 125 mg laktoze monohidrata (glejte poglavje 4.4).
Metabolism and nutrition disorders hypoglycaemia uncommon appetite increased uncommon 
Presnovne in prehranske motnje Hipoglikemija občasni povečan apetit občasni
Tandemact 30 mg/2 mg tablets Tandemact 30 mg/4 mg tablets Tandemact 45 mg/4 mg tablets pioglitazone/glimepiride 
Tandemact 30 mg/2 mg tablete Tandemact 30 mg/4 mg tablete Tandemact 45 mg/4 mg tablete pioglitazon/glimepirid
Infections and infestations upper respiratory tract infection common common sinusitis uncommon uncommon 
Infekcije in parazitske bolezni infekcije zgornjega respiratornega trakta pogosti pogosti
The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness, nausea, coma or convulsion. 
Simptomi so lahko hladno znojenje, utrujenost, glavobol, hitro bitje srca, občutek lakote, razdražljivost, živčnost, siljenje na bruhanje, koma ali krči.
Renal elimination of the two metabolites was impaired. 
Poslabšalo se je ledvično izločanje dveh presnovkov.
The following medicines can increase the blood sugar lowering effect of Tandemact. 
Naslednja zdravila lahko povečajo učinek zdravila Tandemact na zniževanje ravni sladkorja v krvi.
Do not take Tandemact: - if you are allergic to pioglitazone, glimepiride, other sulphonylureas or sulphonamides, or any of the other ingredients of this medicine (listed in section 6) - if you have heart failure or have had heart failure in the past - if you have liver disease - if you have diabetic ketoacidosis (a complication of diabetes with rapid weight loss, nausea or vomiting) - if you have severe problems with your kidneys - if you have or have ever had bladder cancer - if you have blood in your urine that your doctor has not checked - if you have insulin dependent diabetes (type 1) - if you are in a diabetic coma - if you are pregnant - if you are breast-feeding 
Ne jemljite zdravila Tandemact: - če ste alergični na pioglitazon, glimepirid, druge sulfonilsečnine ali sulfonamide ali katero koli sestavino tega zdravila (navedeno v poglavju 6) - če imate srčno popuščanje ali ste imeli srčno popuščanje v preteklosti - če imate obolenje jeter - če imate diabetično ketoacidozo (zaplet sladkorne bolezni z naglo izgubo telesne mase,
The following medicines may decrease the blood sugar lowering effect of Tandemact. 
Naslednja zdravila lahko zmanjšajo učinek zdravila Tandemact na zniževanje ravni sladkorja v krvi.
These are in general reversible upon discontinuation of treatment. 
Po prekinitvi zdravljenja so ta stanja ponavadi reverzibilna.
- allergic reactions including allergic shock - feeling sick (nausea), vomiting and diarrhoea - stomach ache - abdominal pressure - feeling of fullness in the stomach - sensitivity to light - decrease in salt (sodium) concentrations in the blood 
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov) - bolezen jeter - alergijske reakcije, vključno z alergijskim šokom - siljenje na bruhanje (navzea), bruhanje in driska - bolečine v trebuhu - tiščanje v trebuhu - občutek polnosti v želodcu - občutljivost na svetlobo - zmanjšanje koncentracije soli (natrija) v krvi
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Tandemact. 
Zdravilo Tandemact vsebuje laktozo monohidrat Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo zdravila Tandemact posvetujte s svojim zdravnikom.
INFORMATION IN BRAILLE Tandemact 45 mg/4 mg 
PODATKI V BRAILLOVI PISAVI Tandemact 45 mg/4 mg
It is used in adults when metformin is not suitable to treat type 2 (non-insulin dependent) diabetes mellitus. 
Je zdravilo za zdravljenje sladkorne bolezni tipa 2 (od insulina neodvisne sladkorne bolezni) pri odraslih, ko metformin ni primeren.
INFORMATION IN BRAILLE Tandemact 30 mg/2 mg 
PODATKI V BRAILLOVI PISAVI Tandemact 30 mg/2 mg
In general observation in hospital is recommended. 
Zaradi tega je ustrezen ukrep hospitalizacija.
Under the influence of sympatholytic active substances such as betablockers, clonidine, guanethidine and reserpine, the signs of adrenergic counterregulation to hypoglycaemia may be reduced or absent. 
Znaki adrenergične protiregulacije na hipoglikemijo se lahko pod vplivom simpatikolitičnih učinkovin kot so zaviralci beta, klonidin, gvanetidin in reserpin, zmanjšajo ali izginejo.
If a pregnancy occurs, treatment with Tandemact should be discontinued. 
Če se pojavi poslabšanje stanja srca, je treba zdravljenje z zdravilom Tandemact prekiniti.
How to store Tandemact 
Shranjevanje zdravila Tandemact
Your blood sugar will be checked, and your dose of Tandemact may need to be changed. 
Odmerek zdravila Tandemact bo morda treba spremeniti.
Gastrointestinal disorders5 flatulence common vomiting very rare very rare diarrhoea very rare very rare nausea very rare very rare abdominal pain very rare very rare abdominal pressure very rare very rare 
Navzea zelo redki zelo redki bolečine v trebuhu zelo redki zelo redki napetost v trebuhu zelo redki zelo redki občutek polnosti v trebuhu zelo redki zelo redki
INFORMATION IN BRAILLE Tandemact 30 mg/4 mg 
PODATKI V BRAILLOVI PISAVI Tandemact 30 mg/4 mg
What Tandemact looks like and contents of the pack - Tandemact 30 mg/2 mg tablets are white to off-white, round, convex and debossed ‘4833 G' on one face and ‘30/2' on the other. 
Izgled zdravila Tandemact in vsebina pakiranja Tablete Tandemact 30 mg/2 mg so bele do sivobele barve, okrogle, izbočene, z oznako ‘4833 G' na eni in ‘30/2' na drugi strani.
Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of the following active substances is taken, for example: 
Ob jemanju katere izmed naslednjih učinkovin se lahko poveča učinek na znižanje koncentracije glukoze v krvi, zato lahko v nekaterih primerih pride do hipoglikemije:
Marketing authorisation holder Takeda Pharma A/S Dybendal Alle 10 
Imetnik dovoljenja za promet z zdravilom Takeda Pharma A/S
This can lead to a risk of hyperglycaemia (high blood sugar level): - oestrogens, progestogens (female sex hormones) - thiazide diuretics and saluretics also called water tablets (to treat high blood pressure) - levothyroxine (to stimulate the thyroid gland) - glucocorticoids (to treat allergies and inflammation) - chlorpromazine and other phenothiazine derivatives (to treat severe mental disorders) - adrenaline and sympathicomimetics (to increase heart beat, to treat asthma or nasal congestion, 
To lahko povzroči tveganje za hiperglikemijo (visoka raven sladkorja v krvi): - estrogeni, progestogeni (ženski spolni hormoni) - tiazidni diuretiki in saluretiki imenovani tudi zdravila za odvajanje vode (za zdravljenje visokega krvnega tlaka) - levotiroksin (za spodbujanje ščitnice) - glukokortikoidi (za zdravljenje alergij in vnetja) - klorpromazin in drugi fenotiazinski derivati (za zdravljenje hudih duševnih motenj) - adrenalin in simpatikomimetiki (za zvišanje srčnega utripa, za zdravljenje astme ali zamašenega nosu, kašlja in prehlada ali se uporabljajo v življenje-ogrožujočih nujnih primerih) - nikotinska kislina (za zdravljenje zvišane ravni holesterola) - dolgotrajna uporaba odvajal (za zdravljenje zaprtja) - fenitoin (za zdravljenje krčev) - barbiturati (za zdravljenje živčnost in težav s spanjem) - acetazolamid (za zdravljenje povišanega tlaka v očesu, ki se imenuje tudi glavkom) - diazoksid (za zdravljenje visokega krvnega tlaka ali nizke ravni sladkorja v krvi) - rifampicin (za zdravljenje okužb, tuberkuloze) - glukagon (za zdravljenje zelo nizkih ravni sladkorja v krvi)
If you experience this side effect, talk to your doctor as soon as possible. 
Če izkusite ta neželeni učinek, se čim prej posvetujte s svojim zdravnikom.
Each Tandemact 45 mg/4 mg tablet contains 45 mg pioglitazone (as hydrochloride) and 4 mg glimepiride. 
- Ena Tandemact 45 mg/4 mg tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida) in 4 mg glimepirida.
The tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption. 
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktoze ne smejo jemati tega zdravila.
Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur when one of the following active substances is taken, for example: 
Ob jemanju katere izmed naslednjih učinkovin se lahko zmanjša učinek na znižanje koncentracije glukoze v krvi, zato lahko v nekaterih primerih pride do hiperglikemije:
Alertness and reaction time may be impaired due to low or high blood sugar due to glimepiride, especially when beginning or after altering treatment, or when Tandemact is not taken regularly. 
Na začetku ali pri spremembi zdravljenja ali ob nerednem jemanju zdravila Tandemact se lahko poslabša budnost in odzivni čas zaradi nizke ali visoke ravni sladkorja v krvi, ki jo povzroča glimepirid.
A decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ob sočasnem dajanju gemfibrozila bo morda treba znižati odmerek pioglitazona.
Localised swelling (oedema) has also been experienced commonly (may affect up to 1 in 10 people) in patients taking Tandemact in combination with insulin. 
Bolniki ki jemljejo zdravilo Tandemact skupaj z insulinom so pogosto (pri največ 1 od 10 bolnikov) izkusili lokalizirano oteklino (edem).
NAME OF THE MEDICINAL PRODUCT Tandemact 45 mg/4 mg tablets pioglitazone/glimepiride 
IME ZDRAVILA Tandemact 45 mg/4 mg tablete pioglitazon/glimepirid
Tandemact 
Zdravilo Tandemact
Each Tandemact 30 mg/2 mg tablet contains 30 mg pioglitazone (as hydrochloride) and 2 mg glimepiride. 
- Ena Tandemact 30 mg/2 mg tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida) in 2 mg glimepirida.
EU/1/06/366/005 14 tablets EU/1/06/366/006 28 tablets EU/1/06/366/007 30 tablets EU/1/06/366/008 50 tablets EU/1/06/366/009 90 tablets EU/1/06/366/010 98 tablets 
EU/1/06/366/005 14 tablet EU/1/06/366/006 28 tablet EU/1/06/366/007 30 tablet EU/1/06/366/008 50 tablet EU/1/06/366/009 90 tablet EU/1/06/366/010 98 tablet
- weight gain - dizziness - gas - respiratory infection - numbness 
Pogosti (pri največ 1 od 10 bolnikov) - povečanje telesne mase - omotica - vetrovi - okužba dihal - odrevenelost
EU/1/06/366/017 14 tablets EU/1/06/366/018 28 tablets EU/1/06/366/019 30 tablets EU/1/06/366/020 50 tablets EU/1/06/366/021 90 tablets EU/1/06/366/022 98 tablets 
EU/1/06/366/017 14 tablet EU/1/06/366/018 28 tablet EU/1/06/366/019 30 tablet EU/1/06/366/020 50 tablet EU/1/06/366/021 90 tablet EU/1/06/366/022 98 tablet
Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking Tandemact and have also been reported in male patients (frequency cannot be estimated from the available data) taking Tandemact. 
O zlomih so poročali tudi pri bolnikih, ki so se zdravili z zdravilom Tandemact (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
NAME OF THE MEDICINAL PRODUCT Tandemact 30 mg/2 mg tablets pioglitazone/glimepiride 
IME ZDRAVILA Tandemact 30 mg/2 mg tablete pioglitazon/glimepirid
EU/1/06/366/011 14 tablets EU/1/06/366/012 28 tablets EU/1/06/366/013 30 tablets EU/1/06/366/014 50 tablets EU/1/06/366/015 90 tablets EU/1/06/366/016 98 tablets 
EU/1/06/366/011 14 tablet EU/1/06/366/012 28 tablet EU/1/06/366/013 30 tablet EU/1/06/366/014 50 tablet EU/1/06/366/015 90 tablet EU/1/06/366/016 98 tablet
Each Tandemact 30 mg/4 mg tablet contains 30 mg pioglitazone (as hydrochloride) and 4 mg glimepiride. 
- Ena Tandemact 30 mg/4 mg tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida) in 4 mg glimepirida.
HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. 
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, in majhna, statistično neznačilna povišanja ravni LDL holesterola.
Hypersensitivity reactions of the skin may occur as itching, rash, and urticaria. 
Pojavijo se lahko preobčutljivostne reakcije kože, npr. srbenje,
Tandemact 45 mg/4 mg tablets White to off-white, round, flat and debossed ‘4833 G' on one face and ‘45/4' on the other. 
Tandemact 45 mg/4 mg tablete Tablete so bele do sivobele barve, okrogle, ploske z oznako ‘4833 G' na eni in ‘45/4' na drugi strani.
Each tablet contains 45 mg of pioglitazone (as hydrochloride) and 4 mg of glimepiride. 
Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida) in 4 mg glimepirida.
- Tandemact 45 mg/4 mg tablets are white to off-white, round, flat and debossed ‘4833 G' on one face and ‘45/4' on the other. 
Tablete Tandemact 45 mg/4 mg so bele do sivobele barve, okrogle, ploske, z oznako ‘4833 G' na eni in ‘45/4' na drugi strani.
NAME OF THE MEDICINAL PRODUCT Tandemact 30 mg/4 mg tablets pioglitazone/glimepiride 
IME ZDRAVILA Tandemact 30 mg/4 mg tablete pioglitazon/glimepirid
A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. 
Pri bolnikih s sladkorno boleznijo tipa 2 in obstoječo težjo makrovaskularno boleznijo, starih manj kot 75 let, so izvajali študijo kardiovaskularnega izida.
Each tablet contains 30 mg of pioglitazone (as hydrochloride) and 2 mg of glimepiride. 
Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida) in 2 mg glimepirida.
- Tandemact 30 mg/4 mg tablets are white to off-white, round, convex and debossed ‘4833 G' on one face and ‘30/4' on the other. 
Tablete Tandemact 30 mg/4 mg so bele do sivobele barve, okrogle, izbočene, z oznako ‘4833 G' na eni in ‘30/4' na drugi strani.
Each tablet contains 30 mg of pioglitazone (as hydrochloride) and 4 mg of glimepiride. 
Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida) in 4 mg glimepirida.
This can lead to a risk of hypoglycaemia (low blood sugar): - gemfibrozil and fibrates (to lower high cholesterol level) - insulin, metformin or other medicines to treat diabetes mellitus - phenylbutazone, azapropazone, oxyphenbutazone, aspirin-like medicines (to treat pain and inflammation) - long acting sulphonamides, tetracyclines, chloramphenicol, fluconazole, miconazole, 
To lahko povzroči tveganje za hipoglikemijo (nizka raven sladkorja v krvi): - gemfibrozil in fibrati (za zniževanje visoke ravni holesterola) - insulin, metformin ali druga zdravila za zdravljenje sladkorne bolezni
Tandemact is contraindicated during pregnancy (see section 4.3). 
Zdravilo Tandemact je kontraindicirano med nosečnostjo (glejte poglavje 4.3) Če pride do zanositve, je treba zdravljenje z zdravilom Tandemact prekiniti.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 45 mg of pioglitazone (as hydrochloride) and 4 mg of glimepiride. 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida) in 4 mg glimepirida.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 30 mg of pioglitazone (as hydrochloride) and 4 mg of glimepiride. 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida) in 4 mg glimepirida.
STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 30 mg of pioglitazone (as hydrochloride) and 2 mg of glimepiride. 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida) in 2 mg glimepirida.
particularly when pioglitazone is used in combination with insulin (see section 4.4 Fluid retention and cardiac failure). 
Zdravniki morajo začeti zdravljenje z najnižjim odmerkom, ki je na voljo in odmerek zviševati postopoma, še posebej, ko se pioglitazon uporablja v kombinaciji z insulinom (glejte poglavje 4.4 Zastajanje tekočine in srčno popuščanje).
This treatment should be assessed after 12 months. 
To zdravljenje je treba oceniti po 12 mesecih.
Martina Weise (Germany) 
Martina Weise (Nemčija)
The European Commission issued a decision on 27 July 2010. 
Evropska komisija je odločbo izdala 27. julija 2010.
Company responses provided on: 6 April 2009, 11 September 2009, 14 January 2010 and 19 March 2010 
6. aprila 2009, 11. septembra 2009, 14. januarja 2010 in 19. marca 2010
Jens Ersboll (Denmark) 
Jens Ersbøll (Danska)
The company that markets these medicines is Novartis. 
Družba, ki zdravilo trži, je Novartis.
Famvir is authorised in the EU via national procedures. 
Zdravilo Famvir je v EU odobreno z nacionalnimi postopki.
Other sections harmonised include the sections on special warnings, pregnancy and lactation and side effects. 
Druga usklajena poglavja so poglavja s posebnimi opozorili, o nosečnosti in dojenju ter neželenih učinkih.
Famvir is also available in the EU under other trade names: Famciclovir-Sandoz, Famciclovir-SB, Famciclovir-SB Zoster, Famvir Zoster and Oravir. 
Zdravilo Famvir je na voljo v EU tudi pod drugimi imeni: Famciclovir-Sandoz, Famciclovir-SB, Famciclovir-SB Zoster, Famvir Zoster in Oravir.
Why was Famvir reviewed? 
Zakaj je bilo zdravilo Famvir pregledano?
The European Medicines Agency has completed a review of Famvir. 
Evropska agencija za zdravila je zaključila pregled zdravila Famvir.
The CHMP agreed that Famvir should be used for: 
CHMP je potrdil, da se zdravilo Famvir uporablja za:
The blocking of the production of DNA leads to the viruses being unable to multiply. 
Zaradi zaviranja tvorbe DNK se virusi ne morejo razmnoževati.
It is used to treat infection with herpes viruses including varicella zoster which causes shingles, and herpes simplex (HSV) which can cause cold sores or genital herpes. 
Uporablja se za zdravljenje okužbe z virusi herpesa, vključno z virusom varicella zoster, ki povzroča pasovec, in herpesom simpleks (HSV), ki lahko povzroča kožne mehurčke ali genitalni herpes.
This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed. 
To je v različnih državah članicah privedlo do razhajanj glede uporabe zdravila, kakor je razvidno iz povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo v državah, v katerih je zdravilo v prometu.
The Committee recommended that the doses of Famvir should be adjusted in patients with impaired kidney function. 
Odbor je priporočil, da je treba odmerke zdravila Famvir prilagoditi pri bolnikih z oslabljenim delovanjem ledvic.
Famvir should not be used in people who may be hypersensitive (allergic) to famciclovir, penciclovir or to any of the other ingredients. 
Zdravila Famvir ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) famciklovir, penciklovir ali katero koli drugo sestavino zdravila.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Famvir in the European Union (EU). 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji je zaključil, da je treba v Evropski uniji (EU) uskladiti podatke o predpisovanju zdravila Famvir.
Penciclovir is an antiviral. 
Penciklovir je protivirusna učinkovina.
Recurrent episodes should be treated with 125 mg twice a day for five days. 
Pri nadaljnjih ponovitvah je treba dajati 125 mg dvakrat dnevno pet dni.
What is Famvir? 
Kaj je zdravilo Famvir?
The active substance in Famvir, famciclovir, is converted in the body into a substance called penciclovir. 
Zdravilna učinkovina zdravila Famvir, famciklovir, se v telesu pretvori v snov, imenovano penciklovir.
Famvir is an antiviral medicine that contains the active substance famciclovir. 
Famvir je protivirusno zdravilo, ki vsebuje zdravilno učinkovino famciklovir.
• the treatment of herpes zoster (shingles) and ophthalmic zoster (shingles around the eye) in immunocompetent adults (patients with an immune system that works normally); 
• zdravljenje herpesa zoster (pasavca) in oftalmičnega herpesa zoster (pasavca okrog oči) pri imunsko kompetentnih odraslih (bolnikih, pri katerih imunski sistem deluje normalno);
It works by blocking the production of DNA by herpes viruses. 
Deluje tako, da zavira tvorbo DNK, ki jo tvorijo virusi herpesa.
• the treatment of herpes zoster in immunocompromised adults (reduced activity of the immune system); 
• zdravljenje herpesa zoster pri imunsko kompromitiranih bolnikih (zmanjšano delovanje imunskega sistema);
On 27 November 2008, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Famvir and associated names in the EU. 
Da bi Evropska komisija uskladila dovoljenja za promet z zdravilom Famvir in povezanimi imeni v EU, je 27. novembra 2008 zadevo napotila na CHMP.
For herpes zoster, the recommended dose is 500 mg three times a day, for seven days in immunocompetent adults and for ten days in immunocompromised adults. 
Pri herpesu zoster je priporočeni odmerek 500 mg trikrat dnevno sedem dni pri imunsko kompetentnih odraslih oziroma deset dni pri imunsko kompromitiranih odraslih.
For genital herpes in immunocompetent adults, the recommended dose for the first episode is 250 mg three times a day for five days. 
Pri genitalnemu herpesu pri imunsko kompetentnih odraslih je priporočeni odmerek pri prvem pojavu 250 mg trikrat dnevno pet dni.
• the suppression of recurrence of genital herpes in immunocompetent and immunocompromised adults. 
• supresijo ponovitev genitalnega herpesa pri imunsko kompetentnih in imunsko kompromitiranih